304,504 Shares in Compass Therapeutics, Inc. $CMPX Bought by Nuveen LLC

Key Points

• Nuveen LLC acquired 304,504 shares of Compass Therapeutics, Inc. valued at around $579,000, representing approximately 0.22% ownership in the company, according to their recent SEC filing.
• Compass Therapeutics reported a loss of ($0.14) earnings per share, which was below the consensus estimate of ($0.13), and analysts expect a projected loss of -$0.36 earnings per share for the current fiscal year.
• Analysts maintain a consensus "Buy" rating on Compass Therapeutics, with price targets ranging from $9.00 to $32.00, and an average price target of $12.89.

Nuveen LLC purchased a new position in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 304,504 shares of the company's stock, valued at approximately $579,000. Nuveen LLC owned approximately 0.22% of Compass Therapeutics at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of CMPX. Vontobel Holding Ltd. purchased a new stake in shares of Compass Therapeutics during the first quarter valued at $57,000. Squarepoint Ops LLC purchased a new stake in shares of Compass Therapeutics during the fourth quarter valued at $35,000. Price T Rowe Associates Inc. MD boosted its position in shares of Compass Therapeutics by 31.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company's stock valued at $69,000 after buying an additional 11,326 shares during the last quarter. ProShare Advisors LLC boosted its position in Compass Therapeutics by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock worth $42,000 after purchasing an additional 9,451 shares during the last quarter. Finally, Barclays PLC boosted its position in Compass Therapeutics by 13.2% in the fourth quarter. Barclays PLC now owns 192,766 shares of the company's stock worth $279,000 after purchasing an additional 22,521 shares during the last quarter. Institutional investors own 68.43% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Guggenheim increased their price objective on shares of Compass Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a research note on Tuesday, August 12th. D. Boral Capital reiterated a "buy" rating and issued a $32.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, August 12th. Finally, Raymond James Financial raised Compass Therapeutics to an "outperform" rating and set a $9.00 price objective on the stock in a research report on Tuesday, July 1st. One analyst has rated the stock with a Strong Buy rating and nine have given a Buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $12.89.

Compass Therapeutics Stock Performance

CMPX traded down $0.00 during trading on Tuesday, reaching $3.44. 68,994 shares of the company traded hands, compared to its average volume of 1,371,267. Compass Therapeutics, Inc. has a 12-month low of $1.27 and a 12-month high of $4.08. The firm has a fifty day simple moving average of $3.03 and a 200 day simple moving average of $2.47. The company has a market cap of $475.13 million, a P/E ratio of -7.64 and a beta of 1.50.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01). As a group, sell-side analysts expect that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current fiscal year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.